Discovery of a Chiral DNA‐Targeted Platinum–Acridine Agent with Potent Enantioselective Anticancer Activity

A structure–activity relationship study was performed for a set of rigidified platinum–acridine anticancer agents containing linkers derived from chiral pyrrolidine and piperidine scaffolds. Screening a library of microscale reactions and selected resynthesized compounds in non‐small‐cell lung cance...

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie 2020-12, Vol.132 (49), p.22149-22154
Main Authors: Zhang, Shenjie, Yao, Xiyuan, Watkins, Noah H., Rose, P. Keegan, Caruso, Sofia R., Day, Cynthia S., Bierbach, Ulrich
Format: Article
Language:English
Subjects:
Acridine
Anticancer properties
Antitumor activity
Antitumor agents
Chemistry
Deoxyribonucleic acid
DNA
DNA adducts
drug design
Enantiomers
Lung cancer
NCI-60 screening
Non-small cell lung carcinoma
non-small-cell lung cancer
Piperidine
Platinum
Pyrrolidine
Screening
Solid tumors
spectrum of activity
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A structure–activity relationship study was performed for a set of rigidified platinum–acridine anticancer agents containing linkers derived from chiral pyrrolidine and piperidine scaffolds. Screening a library of microscale reactions and selected resynthesized compounds in non‐small‐cell lung cancer (NSCLC) cells showed that cytotoxicities varied by more than three orders of magnitude. A potent hit compound was discovered containing a (R)‐N‐(piperidin‐3‐yl) linker (P2‐6R), which killed NCI‐H460 and A549 lung cancer cells 100 times more effectively than the S enantiomer (P2‐6S). P2‐6R accumulated in A549 cells significantly faster and produced 50‐fold higher DNA adduct levels than P2‐6S. Ligand similarity analysis suggests that only module 6R may be compatible with strainless monofunctional intercalative binding. NCI‐60 screening and COMPARE analysis highlights the spectrum of activity and potential utility of P2‐6R for treating NSCLC and other solid tumors. Modular library screening identified a case of highly enantioselective anticancer activity in rigidified, DNA‐targeted platinum–acridine agents. A hit compound, P2‐6R, was identified that shows high potency in chemoresistant cancers and an activity profile across 60 cancer cell lines (NCI‐60) complementary to that of cisplatin and other clinically relevant platinum‐based drugs.
ISSN:0044-8249
1521-3757
DOI:10.1002/ange.202009983